ArticleAesthetic plastic surgery2025
Injection of the Concentrate Derived from Nanofat Graft Promotes Hair Growth in Patients of Male Androgenetic Alopecia: A Clinical Pilot Study.
Article in Aesthetic plastic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07518342 (Efficacy and Safety of Nanofat Injection vs Either PRP Injection or Topical Minoxidil 5% in Female and Male Pattern Androgenetic Alopecia), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Nanofat Injection vs Either PRP Injection or Topical Minoxidil 5% in Female and Male Pattern Androgenetic Alopecia
Who cites it
2 citing papers in PubMed.
- The Role of dWAT-Immune Crosstalk in Hair Follicle Microenvironment in Hair Regeneration.The Journal of dermatology · 2026Review
- Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes.Medical sciences (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAndrogenetic alopecia (AGA) is the most common hair loss disorder in men. Adipose-derived stem cells (ADSCs) have shown regenerative potential, but their clinical application is hindered by complex processing. Concentrate derived from nanofat graft (CDNF), rich in ADSCs, promotes hair growth in mice, suggesting its potential clinical efficacy.
objectiveThis study aimed to assess the efficacy of intradermal CDNF injection as a novel autologous therapeutic approach for AGA.
methodsTen male AGA patients (Norwood-Hamilton III-VI, aged 22-38) received three CDNF injections (0.25ml/cm
resultsAll patients exhibited hair regeneration at all follow-ups. Significant improvements were observed not only in total hair count but also in hair diameter and pigmentation. Quantitative analysis revealed a significant increase in the number of hairs with a diameter >0.03 mm at all follow-up time points. Conversely, the number of hairs with a diameter ≤0.03 mm demonstrated a notable decrease at the 3- and 6-month assessments. Peak efficacy was observed at 12 months post-injection, with total hair counts significantly exceeding baseline levels. No severe adverse events were reported. Furthermore, treatment outcomes showed no significant variation with patient age.
conclusionsIntradermal CDNF injection is an efficacious and safe regenerative therapy for male AGA, suggesting that this regenerative therapy may serve as a promising alternative treatment option for hair loss. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Indexed as
Identifiers
41028613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.